JKT · SRAJ.JK
PT Sejahteraraya Anugrahjaya Tbk
IDR 10,850-IDR 125 (-1.14%)
PT Sejahteraraya Anugrahjaya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.49% below the high.
Loading market information…
JKT · DGNS.JK · IDR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:02 AM UTC. Cached market data; not a live quote.
One-year closing-price history · IDR. Historical prices are not a forecast.
PT Diagnos Laboratorium Utama Tbk’s quoted price sits in the upper half of its reported 52-week range, 27.23% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PT Diagnos Laboratorium Utama Tbk’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PT Diagnos Laboratorium Utama Tbk delivers comprehensive medical laboratory services across Indonesia. The company offers a wide range of diagnostic tests, including clinical pathology services covering hematology, hemostasis, clinical chemistry, urinalysis, biomolecular analysis, immunology, and microbiology. It also performs anatomical pathology for the detailed examination of tissues and body fluids. Furthermore, PT Diagnos specializes in advanced genomics testing, such as non-invasive prenatal screening (NIPT) and preimplantation genetic testing for both aneuploidy and monogenic diseases. Beyond its core laboratory offerings, the company provides convenient home-based health check-ups, tailored corporate wellness programs, and specialized COVID-19 testing. Its broader involvement extends to supporting various healthcare initiatives and infrastructure, including maintaining specialized biological banks (e.g., eye, blood, sperm, and organ banks) and pharmacy warehousing, in collaboration with both public and private sector entities. Established in 2007, the company's headquarters are located in Jakarta Pusat, Indonesia.
Latest available per-share figures in IDR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
IDR 10,850-IDR 125 (-1.14%)
PT Sejahteraraya Anugrahjaya Tbk’s quoted price sits in the lower half of its reported 52-week range, 43.49% below the high.
IDR 730+IDR 15 (+2.1%)
PT Kalbe Farma Tbk.’s quoted price sits in the lower half of its reported 52-week range, 45.52% below the high.
IDR 1,880-IDR 20 (-1.05%)
PT Siloam International Hospitals Tbk’s quoted price sits in the lower half of its reported 52-week range, 34.72% below the high.
IDR 123+IDR 1 (+0.82%)
PT Royal Prima Tbk’s quoted price sits in the upper half of its reported 52-week range, 8.21% below the high.
IDR 198IDR 0 (0.0%)
PT Millennium Pharmacon International Tbk’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
IDR 254IDR 0 (0.0%)
PT Phapros, Tbk’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
IDR 24-IDR 2 (-7.69%)
PT Nanotech Indonesia Global Tbk’s quoted price sits in the lower half of its reported 52-week range, 64.18% below the high.
IDR 58-IDR 3 (-4.92%)
PT Hetzer Medical Indonesia Tbk’s quoted price sits in the lower half of its reported 52-week range, 63.06% below the high.
